HOOKIPA Pharma Inc. (HOOK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joern Aldag | CEO & Director | 848.34k | -- | 1959 |
| Dr. Reinhard Kandera Ph.D. | CFO & Director | 607.5k | -- | 1969 |
| Prof. Rolf M. Zinkernagel M.D., Ph.D. | Co-Founder | -- | -- | 1944 |
| Mr. Andreas Bergthaler | Co-Founder | -- | -- | -- |
| Mr. Lukas Flatz | Co-Founder | -- | -- | -- |
| Dr. Roman Necina Ph.D. | Chief Operations Officer | -- | -- | 1968 |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer | -- | -- | 1978 |
| Mr. Matthew L. S. Beck | Executive Director of Investor Relations | -- | -- | -- |
| Mr. Michael Szumera | Executive Director of Communications | -- | -- | -- |
| Dr. Mark Winderlich Ph.D. | Chief Development Officer | -- | -- | 1986 |
HOOKIPA Pharma Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 151
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
August 8, 2024 at 12:30 PM UTC - August 12, 2024 at 12:30 PM UTC
HOOKIPA Pharma Inc. Earnings Date